The estimated Net Worth of Terry Ann Burrell is at least 8.54 百万$ dollars as of 1 April 2024. Ms. Burrell owns over 5,446 units of Beam Therapeutics stock worth over 1,691,704$ and over the last 4 years she sold BEAM stock worth over 2,548,931$. In addition, she makes 4,302,720$ as Chief Financial Officer、 Treasurer at Beam Therapeutics.
Terry has made over 10 trades of the Beam Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 5,446 units of BEAM stock worth 174,926$ on 1 April 2024.
The largest trade she's ever made was selling 47,195 units of Beam Therapeutics stock on 18 January 2023 worth over 2,130,382$. On average, Terry trades about 13,992 units every 81 days since 2020. As of 1 April 2024 she still owns at least 70,137 units of Beam Therapeutics stock.
You can see the complete history of Ms. Burrell stock trades at the bottom of the page.
Terry-Ann Burrell serves as Chief Financial Officer, Treasurer of the Company. From May 2008 to August 2019, Ms. Burrell worked at J.P. Morgan Securities LLC, where she most recently served as Managing Director. Ms. Burrell was responsible for deal execution across both mergers and acquisitions and capital markets. In her role, she advised biotechnology and pharmaceutical companies on strategic considerations, including mergers and acquisitions, initial public and secondary offerings and valuation analysis. Ms. Burrell holds a bachelor’s degree from Harvard College and an MBA from New York University’s Leonard N. Stern School of Business.
As the Chief Financial Officer、 Treasurer of Beam Therapeutics, the total compensation of Terry Burrell at Beam Therapeutics is 4,302,720$. There are no executives at Beam Therapeutics getting paid more.
Terry Burrell is 42, she's been the Chief Financial Officer、 Treasurer of Beam Therapeutics since 2019. There are 14 older and 1 younger executives at Beam Therapeutics. The oldest executive at Beam Therapeutics Inc. is Mark Fishman, 68, who is the Independent Director.
Terry's mailing address filed with the SEC is C/O BEAM THERAPEUTICS INC.,, 238 MAIN STREET, CAMBRIDGE, MA, 02142.
Over the last 5 years, insiders at Beam Therapeutics have traded over 63,012,019$ worth of Beam Therapeutics stock. The most active insiders traders include Group, Llc Green Jeremy Red...、Llc Fmr、Kristina Burow. On average, Beam Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of 1,019,987$. The most recent stock trade was executed by Amy Simon on 1 July 2024, trading 1,250 units of BEAM stock currently worth 29,100$.
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Beam Therapeutics executives and other stock owners filed with the SEC include: